Newsletter
Subscribe and receive updates on this company
Text STOCKS to 72727 for mobile alerts
We are excited to present Amarantus Bioscience Holdings, Inc. (OTC: AMBS).
* Cover Mode Short Analysis provided by Squeeze Report. Recent News from (OTC: AMBS)
Amarantus to Present at the Planet MicroCap Showcase 2018 in Las Vegas NEW YORK , NY / ACCESSWIRE / April 20, 2018 / Amarantus Bioscience Holdings, Inc. (OTC PINK: AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its su... Source: ACCESSWIRE Date: April, 20 2018 08:00 Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic ... Source: GlobeNewswire Date: April, 16 2018 07:31 Amarantus BioScience (AMBS) Presents At MicroCap Conference 2018 - Slideshow The following slide deck was published by Amarantus Bioscience Holdings, Inc. in conjunction with this Read more ... Source: SeekingAlpha Date: April, 11 2018 13:02 SeeThruEquity Issues Update on Amarantus Bioscience Holdings, Inc. NEW YORK, NY / ACCESSWIRE / April 10, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Amarantus Bioscience Holdings, Inc. (OTC PINK: AMBS). The report is av... Source: ACCESSWIRE IA Date: April, 10 2018 09:45 Amarantus to Present at The Microcap Conference in NYC NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic thera... Source: GlobeNewswire Date: April, 09 2018 13:09 Amarantus Re-acquires Rights to Alzheimer's Blood Diagnostic LymPro Test NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therap... Source: GlobeNewswire Date: April, 06 2018 11:23 Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic ther... Source: GlobeNewswire Date: April, 05 2018 08:00 Amarantus Relocates Headquarters to WeWork at 110 Wall St. in New York City SAN FRANCISCO, April 02, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalm... Source: GlobeNewswire Date: April, 02 2018 09:49 Amarantus Completes Tender Exchange of Convertible Securities; CEO attending CNBC's Healthy Returns conference in New York City SAN FRANCISCO, March 28, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS ) (the "Company" or AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ... Source: GlobeNewswire Date: March, 28 2018 13:41 Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia SAN FRANCISCO, March 08, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), advancing Eltoprazine into a Phase 2b trial for the treatment of the orphan indic... Source: GlobeNewswire Date: March, 08 2018 08:00 Last 5 Days Trading Activity
Date Open Price Close Price High Low Volume 2018-04-21 0.0408 0.039871 0.0408 0.037 1,118,955 2018-04-20 0.0408 0.039871 0.0408 0.037 1,118,955 2018-04-19 0.045 0.0408 0.045 0.04 803,352 2018-04-18 0.0475 0.0434 0.0475 0.0434 1,155,711 2018-04-17 0.046 0.0455 0.049 0.0447 793,193 Last 5 Days Short Activity
Date Short Volume Total Volume Short Percentage Short Indicator 2018-04-20 291,954 1,018,955 28.6523 Cover 2018-04-19 151,619 569,877 26.6056 Cover 2018-04-18 339,491 1,007,934 33.6819 Cover 2018-04-17 25,178 493,193 5.1051 Cover 2018-04-16 70,290 208,737 33.6740 Cover
About Amarantus Bioscience Holdings, Inc. (OTC: AMBS)
Amarantus Bioscience Holdings AMBS is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS wholly owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase b ready small molecule indicated for Parkinson s disease levodopa induced dyskinesia, Alzheimer s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program ESS , a regenerative medicine based approach for treating severe burns with full thickness autologous skin grown in tissue culture that is being pursued by AMBS wholly owned subsidiary Cutanogen Corporation. AMBS wholly owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte derived neurotrophic factor MANF . MANF Therapeutics, Inc. is developing MANF based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS proprietary discovery engine PhenoGuard. AMBS also owns approximately . million shares of Avant Diagnostics, Inc. via the sale of its wholly owned subsidiary Amarantus Diagnostics, Inc. that occurred in May .
Contact Information
- Website: http://www.amarantus.com/
- Phone: 6508625391
- Email: info@amarantus.com
- Twitter: https://twitter.com/amarantusbio
- Facebook: https://www.facebook.com/amarantusbio
Current Management
- Gerald E. Commissiong / CEO, President, COO
- John W. Commissiong / CSO
- Gerald E. Commissiong /
- John W. Commissiong /
- Robert L. Harris / Independent Director
- Donald D. Huffman / Independent Director
- Steve Spence / Independent Director
- Steven Spence / Independent Director
Current Share Structure
- Market Cap: $7,459,696 - 03/20/2018
- Authorized: 250,000,000 - 03/01/2018
- Issue and Outstanding: 135,630,841 - 03/01/2018
- Float: 75,956,228 - 12/06/2017
Recent Filings from (OTC: AMBS)
| Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Information | ||
| Filing Type: Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Inform | Filing Source: OTC Markets | |
| Filing Date: December, 08 2017 | ||
| Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Information | ||
| Filing Type: Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Inform | Filing Source: OTC Markets | |
| Filing Date: December, 08 2017 | ||
| Quarterly Report - Amarantus 2017 Q1-Q3 2017 | ||
| Filing Type: Quarterly Report - Amarantus 2017 Q1-Q3 2017 | Filing Source: OTC Markets | |
| Filing Date: December, 07 2017 | ||
| Annual Report - Amarantus 2016 Fiscal Year 2016 | ||
| Filing Type: Annual Report - Amarantus 2016 Fiscal Year 2016 | Filing Source: OTC Markets | |
| Filing Date: December, 07 2017 | ||
| Quarterly Report - OTC Pink Disclosure Guidelines Q3-2017 | ||
| Filing Type: Quarterly Report - OTC Pink Disclosure Guidelines Q3-2017 | Filing Source: OTC Markets | |
| Filing Date: December, 07 2017 | ||
| Annual Report - OTC Pink Disclosure Guidelines | ||
| Filing Type: Annual Report - OTC Pink Disclosure Guidelines | Filing Source: OTC Markets | |
| Filing Date: December, 07 2017 | ||
| Certification of termination of registration of a class of security under Section 12(g) or notice of suspension of duty to file reports under Section 13 and 15(d) of the Act Section 12 (g). | ||
| Filing Type: 15-12G | Filing Source: edgar | |
| Filing Date: December, 04 2017 | ||
| Report of unscheduled material events or corporate changes. | ||
| Filing Type: 8-K | Filing Source: edgar | |
| Filing Date: May, 09 2017 | ||
| Report of unscheduled material events or corporate changes. | ||
| Filing Type: 8-K | Filing Source: edgar | |
| Filing Date: April, 17 2017 | ||
| Report of unscheduled material events or corporate changes. | ||
| Filing Type: 8-K | Filing Source: edgar | |
| Filing Date: March, 28 2017 | ||
Daily Technical Chart for (OTC: AMBS)
It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter Stay tuned for daily updates and more on (OTC: AMBS)
More to come on (OTC: AMBS)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Thank you The Subway Trader Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AMBS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of AMBS and does not buy, sell, or trade any shares of AMBS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/
@TheSubwayTrader
Release this Report to Investors
Via Email
Via Text
Important
If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us